Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dolphin Medical ServicesBOM:526504 37 EV-to-EBITDA is 71.91 as of Aug. 27, 2026. GuruFocus rates BOM:526504 with a GF Score™ of 37/100 and a GF Value™ of ₹2.59 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Dolphin Medical Services ranks worse than 94.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dolphin Medical Services's enterprise value is ₹113.91 Mil.
Dolphin Medical Services's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹1.58 Mil. Therefore, Dolphin Medical Services's EV-to-EBITDA for today is 71.91.
The historical rank and industry rank for Dolphin Medical Services's EV-to-EBITDA or its related term are showing as below:
BOM:526504'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -284.27 Med: -15.08 Max: 4255.45
Current: 71.91
During the past 13 years, the highest EV-to-EBITDA of Dolphin Medical Services was 4255.45. The lowest was -284.27. And the median was -15.08.
BOM:526504's EV-to-EBITDA is ranked worse than 94.07% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.44
vs BOM:526504: 71.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dolphin Medical Services (BOM:526504) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dolphin Medical Services's PE Ratio (TTM) for today is calculated as:
Dolphin Medical Services's share price for today is ₹6.98.
Dolphin Medical Services's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526504 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's EV-to-EBITDA falls into.
Dolphin Medical Services's current Enterprise Value is ₹113.91 Mil.
Dolphin Medical Services's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dolphin Medical Services (BOM:526504) has a EV-to-EBITDA of 71.91 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dolphin Medical Services. According to the industry distribution chart, Dolphin Medical Services ranks #111 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 94.1%.
Is Dolphin Medical Services' EV-to-EBITDA too high?
Dolphin Medical Services' current EV-to-EBITDA is 71.91. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.44. Dolphin Medical Services' value of 71.91 is 337.4% above this industry median. Based on the distribution chart, Dolphin Medical Services ranks #111 out of 118 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Dolphin Medical Services has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dolphin Medical Services ranks #111 out of 118 companies for EV-to-EBITDA. This places Dolphin Medical Services in the lower half of its industry. The industry median EV-to-EBITDA is 16.44. Dolphin Medical Services' value of 71.91 is 337.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.44, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dolphin Medical Services's current EV-to-EBITDA of 71.91 is 337.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dolphin Medical Services. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dolphin Medical Services's current EV-to-EBITDA is 71.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.59, compared to a current price of ₹6.98 — trading 169.5% above its estimated fair value. The current EV-to-EBITDA is 71.91 and 337.4% above the Medical Diagnostics & Research industry median of 16.44. Dolphin Medical Services' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current EV-to-EBITDA is 71.91 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹6.98 is trading 169.5% above its estimated GF Value™ of ₹2.59.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
EV-to-EBITDA: 71.91
GF Value™: ₹2.59 vs. price of ₹6.98 (169.5% above fair value)
Industry Position: 337.4% above the Medical Diagnostics & Research median (#111 of 118)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
37GF Score
Get the complete analysis for BOM:526504
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
